Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 69 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Lurasidone Clear all
Completed Phase 2 Interventional Results available

Safety and Tolerability Study of Drug to Treat Schizophrenia

NCT00044005
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone 20 mg, Lurasidone 40 mg, Lurasidone 80mg
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
26
States / cities
Birmingham, Alabama • Cerritos, California • Garden Grove, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Oct 17, 2026, 1:29 AM EDT
Completed Phase 1 Interventional Results available

A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia

NCT03627195
View directory record Official record
Conditions
Schizophrenia
Interventions
DSP-1349M, placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated May 8, 2020 · Synced Oct 17, 2026, 1:29 AM EDT
Completed Phase 3 Interventional Results available

Lurasidone Pediatric Autism Study

NCT01911442
View directory record Official record
Conditions
Autism
Interventions
Lurasidone 20 mg daily, Lurasidone, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
41
States / cities
Dothan, Alabama • Phoenix, Arizona • Newport Beach, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Oct 17, 2026, 1:29 AM EDT
Completed Phase 1 Interventional

Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl

NCT01074632
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder
Interventions
Lurasidone HCl
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Glendale, California • Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2011 · Synced Oct 17, 2026, 1:29 AM EDT
Completed Phase 1 Interventional

Lithium Drug-Drug Interaction Study With Lurasidone HCl

NCT01074073
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone HCl
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2011 · Synced Oct 17, 2026, 1:29 AM EDT
Completed Phase 3 Interventional Results available

Lurasidone Low-Dose - High-Dose Study Study

NCT01821378
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone, Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
28
States / cities
Little Rock, Arkansas • Cerritos, California • Escondido, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Oct 17, 2026, 1:29 AM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Broadband Near Infrared Spectroscopy to Understand the Role of Brain Cytochrome C Oxidase in Bipolar Disorder

NCT07806227
View directory record Official record
Conditions
Bipolar Disorder Depression
Interventions
Lurasidone (Latuda)
Drug
Lead sponsor
Martin Lan
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 17, 2026, 1:29 AM EDT
Completed Phase 3 Interventional Results available

Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia

NCT00615433
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone, Olanzapine, Placebo comparator, Lurasidone 40 mg tablets
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
25
States / cities
Little Rock, Arkansas • Cerritos, California • Oceanside, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2015 · Synced Oct 17, 2026, 1:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized, Placebo-Controlled, Two-Period, Crossover Study to Evaluate the Effect of Lurasidone HCl on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects

NCT00549666
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Lurasidone 40 mg, Placebo 40 mg, Ortho Tri-Cyclen
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2011 · Synced Oct 17, 2026, 1:29 AM EDT
Not listed Not applicable Interventional

Antidepressant Discontinuation in Treatment Resistant Depression

NCT03786614
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Discontinuation of serotonergic antidepressants, Continuation of serotonergic medications
Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 17, 2026, 1:29 AM EDT
Completed Phase 4 Interventional Results available

18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder

NCT03902613
View directory record Official record
Conditions
Bipolar Depression
Interventions
Lurasidone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 17, 2026, 1:29 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone

NCT01173874
View directory record Official record
Conditions
Schizophrenia
Interventions
Cognitive Remediation
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
16
States / cities
Granada Hills, California • Orange, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 17, 2026, 1:29 AM EDT
Completed Phase 3 Interventional Results available

Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia

NCT00789698
View directory record Official record
Conditions
Chronic Schizophrenia
Interventions
Lurasidone HC1, Quetiapine XR
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
27
States / cities
Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2015 · Synced Oct 17, 2026, 1:29 AM EDT
Completed Phase 2Phase 3 Interventional

NRX-101 for Bipolar Depression With Subacute Suicidal Ideation

NCT03395392
View directory record Official record
Conditions
Bipolar Depression, Suicidal Ideation and Behavior
Interventions
NRX-101, Lurasidone HCl
Drug
Lead sponsor
NeuroRx, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
14
States / cities
Culver City, California • Miami Lakes, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 17, 2026, 1:29 AM EDT
Completed No phase listed Observational

Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment

NCT01364818
View directory record Official record
Conditions
Autism Spectrum Disorders, Psychosis, Fragile X Syndrome
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
3 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Oct 17, 2026, 1:29 AM EDT
Completed Phase 1 Interventional Results available

Lurasidone Pediatric Pharmacokinetics Study

NCT01620060
View directory record Official record
Conditions
Schizophrenia, Autism
Interventions
Lurasidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
10
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Murrieta, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 17, 2026, 1:29 AM EDT
Completed Phase 3 Interventional Results available

Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose

NCT01421134
View directory record Official record
Conditions
Major Depressive Disorder With Mixed Features
Interventions
Lurasidone, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
19
States / cities
Birmingham, Alabama • Escondido, California • Garden Grove, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2016 · Synced Oct 17, 2026, 1:29 AM EDT
Completed Phase 2 Interventional Results available

A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia

NCT00088634
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
22
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 17, 2026, 1:29 AM EDT
Completed Phase 3 Interventional Results available

Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)

NCT00868452
View directory record Official record
Conditions
Bipolar Depression
Interventions
lurasidone + (lithium or divalproex), Placebo + (lithium or divalproex)
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
27
States / cities
Little Rock, Arkansas • Anaheim, California • Chino, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Oct 17, 2026, 1:29 AM EDT
Completed Phase 3 Interventional Results available

Major Depressive Disorder With Mixed Features - Extension

NCT01423253
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Lurasidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
17
States / cities
Birmingham, Alabama • Escondido, California • Garden Grove, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 17, 2026, 1:29 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial

NCT07227103
View directory record Official record
Conditions
Treatment Resistant Depression, Treatment Resistant Depression (TRD)
Interventions
Neuronavigated robotic-enabled TMS, NRX-101, Sham TMS, Oral Placebo
Device · Drug
Lead sponsor
NeuroRx, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Sarasota, Florida • West Palm Beach, Florida • Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 1:29 AM EDT
Completed Phase 2 Interventional Results available

Sequential Therapy for the Treatment of Severe Bipolar Depression.

NCT02974010
View directory record Official record
Conditions
Bipolar Depression, Suicidal Ideas, Suicidal Ideation, Suicide, Attempted
Interventions
NRX-101 Oral Capsule, Lurasidone Oral Capsule, Ketamine Intravenous Infusion, Saline Solution Intravenous Infusion
Drug
Lead sponsor
NeuroRx, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Birmingham, Alabama • Fort Lauderdale, Florida • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 17, 2026, 1:29 AM EDT
Completed Phase 3 Interventional Results available

Pediatric Open-Label Extension Study

NCT01914393
View directory record Official record
Conditions
Schizophrenia, Autism, Bipolar Depression
Interventions
Lurasidone 20, 40, 60, 80 mg, flexibly dosed
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
35
States / cities
Dothan, Alabama • Downey, California • San Francisco, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced Oct 17, 2026, 1:29 AM EDT
Completed Phase 3 Interventional Results available

Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia

NCT00549718
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone HCl
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
489 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
21
States / cities
Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2014 · Synced Oct 17, 2026, 1:29 AM EDT